S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:PIRS

Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis

$0.18
-0.01 (-5.18%)
(As of 03/28/2024 ET)
Today's Range
$0.18
$0.19
50-Day Range
$0.16
$0.22
52-Week Range
$0.14
$1.29
Volume
398,605 shs
Average Volume
593,851 shs
Market Capitalization
$18.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Pieris Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.76mentions of Pieris Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.35) to ($0.20) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.78 out of 5 stars

Medical Sector

374th out of 938 stocks

Pharmaceutical Preparations Industry

168th out of 423 stocks

PIRS stock logo

About Pieris Pharmaceuticals Stock (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

PIRS Stock Price History

PIRS Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
PIRS Apr 2024 2.500 call
Pieris Pharmaceuticals Inc (PIRS)
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Pieris Pharmaceuticals, Inc. (PIRS)
Pieris Pharmaceuticals Inc PIRS
Pieris Pharma Cuts Around 70% Workforce; Plans Strategic Options
Pieris Pharmaceuticals (NASDAQ: PIRS)
See More Headlines
Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/28/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PIRS
Employees
127
Year Founded
N/A

Profitability

Net Income
$-33,280,000.00
Pretax Margin
-59.25%

Debt

Sales & Book Value

Annual Sales
$25.90 million
Book Value
$0.38 per share

Miscellaneous

Free Float
90,064,000
Market Cap
$18.65 million
Optionable
Optionable
Beta
0.48
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Stephen S. Yoder J.D. (Age 48)
    CEO, President & Director
    Comp: $774.72k
  • Mr. Thomas Bures (Age 50)
    Senior VP & CFO
    Comp: $499.38k
  • Maria Kelman
    Executive Director of Investor Relations
  • Mr. Frank Vollmering
    Vice President of Human Resources
  • Dr. Shane Olwill Ph.D. (Age 48)
    Senior VP & Chief Development Officer
  • Mr. Prompong Chaikul (Age 37)
    Chief Supply Chain Officer
  • Dr. Florian Witte Ph.D.
    VP and Head of Alliance Management & Early Project Leadership

PIRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Pieris Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" PIRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PIRS, but not buy additional shares or sell existing shares.
View PIRS analyst ratings
or view top-rated stocks.

How have PIRS shares performed in 2024?

Pieris Pharmaceuticals' stock was trading at $0.1820 at the beginning of 2024. Since then, PIRS shares have increased by 0.7% and is now trading at $0.1832.
View the best growth stocks for 2024 here
.

Are investors shorting Pieris Pharmaceuticals?

Pieris Pharmaceuticals saw a decline in short interest in March. As of March 15th, there was short interest totaling 41,600 shares, a decline of 41.2% from the February 29th total of 70,700 shares. Based on an average trading volume of 619,200 shares, the days-to-cover ratio is currently 0.1 days.
View Pieris Pharmaceuticals' Short Interest
.

When is Pieris Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our PIRS earnings forecast
.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) posted its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.24) earnings per share for the quarter, hitting the consensus estimate of ($0.24). The biotechnology company had revenue of $4.06 million for the quarter, compared to the consensus estimate of $7.98 million. Pieris Pharmaceuticals had a negative net margin of 59.25% and a negative trailing twelve-month return on equity of 98.12%. During the same quarter last year, the company earned ($0.26) EPS.

What other stocks do shareholders of Pieris Pharmaceuticals own?
Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (0.92%), Vanguard Group Inc. (0.92%), Northern Trust Corp (0.25%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher P Kiritsy, Shane Olwill and Tim Demuth.
View institutional ownership trends
.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PIRS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners